Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.

Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts

Learn more Maze Therapeutics, Inc. (NASDAQ:MAZE) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have ...
Morningstar

Maze Therapeutics Inc MAZE

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Cat Surprises Owner by Solving Maze in Seconds

Cats are curious, observant, and surprisingly clever when it comes to navigating their surroundings. Many feline parents have ...
Business Wire

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the U.S. Federal Trade Commission (FTC) has filed ...
Business Wire

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 ...